ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1345	National Cancer Institute	Html	en	Where To Get Help When You Decide To Quit Smoking	This fact sheet provides information about helpful resources for people who have decided to quit smoking.	pregnant smokers 0.551074 Monday 0.355736 health care provider 0.663743 Human Services 0.458787 smoking quitline 0.772173 past failures 0.456683 Control Research Branch 0.617264 online instant 0.460766 good sources 0.488807 fact sheet 0.479049 Disease Control 0.471166 Friday 0.356769 Spanish 0.352479 cessation counselors 0.66457 Handle Withdrawal Symptoms 0.626098 tobacco users 0.460764 local resources 0.610693 health care professionals 0.901235 Smokefree.gov Web site 0.887035 local cessation programs 0.636749 National Institutes 0.468631 a.m. 0.357414 toll-free number routes 0.602386 toll-free telephone quitline 0.609664 smoking-related questions 0.477461	NCI 0.448064 nicotine replacement products 0.63931 free materials 0.471513 Forever Free 0.465092 LiveHelp 0.389817 state-run quitlines 0.469544 support 0.389277 wide range 0.469675 resource information 0.468257 United States 0.462426 smokers 0.602948 specific action 0.452212 Express things 0.451457 smoking 0.882754 national resources 0.480672 free cessation assistance 0.632049 Eastern time 0.627286 smoking materials 0.639653 potential side effects 0.490412 Clear Horizons 0.464946 English 0.352498 science-driven tools 0.47693 one-on-one help 0.476837 information 0.470963	CLICK HERE
1440	National Cancer Institute	Html	en	Genetics of Colorectal Cancer (PDQ®)–Health Professional Version	Hereditary colorectal cancer syndromes include Lynch syndrome and several polyposis syndromes (familial adenomatous polyposis, MUTYH-associated polyposis, juvenile polyposis syndrome, Peutz-Jeghers syndrome, and serrated polyposis syndrome). Learn about the genetics, clinical manifestations, management, and psychosocial aspects of these and other hereditary colon cancer syndromes in this expert-reviewed summary.	hyperplastic polyps 0.725031 nondysplastic serrated polyps 0.656585 adenomatous polyps 0.691874 classic FAP burden 0.649593 colonic polyps 0.652581 colorectal cancer risk 0.652487 FAP patients 0.932715 colorectal cancer screening 0.641111 familial CRC risk 0.634448 duodenal adenomas 0.717785 polyps 0.898156 colorectal cancer 0.915758 large serrated polyps 0.681431 conventional hyperplastic polyps 0.657048 rectal cancer risk 0.636363 hereditary nonpolyposis colorectal 0.723285 CRC 0.676743 colorectal adenomatous polyps 0.677785 APC pathogenic variant 0.710503 familial adenomatous polyposis 0.637625 et al. 0.674027 adenomas 0.856618 study 0.666989 nonpolyposis colorectal cancer 0.748743 duodenal polyps 0.793499	polyp burden 0.773382 FAP family member 0.659403 hereditary colon cancer 0.646397 unselected CRC patients 0.633325 CpG island methylator 0.649466 Lynch syndrome patients 0.681837 pathogenic variants 0.757278 Advanced colorectal polyps 0.671186 serrated adenomas 0.645858 FAP families 0.629309 large adenomas 0.639406 Lynch syndrome 0.829151 FAP polyp burden 0.677536 colon cancer 0.807611 Abstract 0.653383 uncontrolled rectal polyps 0.639399 island methylator phenotype 0.649038 duodenal polyp burden 0.68665 FAP patients. 0.679148 SPS polyps 0.632287 family history 0.768195 cancer risk 0.699194 rectal cancer patients 0.661401 classic FAP 0.64982	CLICK HERE
1569	National Cancer Institute	Html	en	Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of mycosis fungoides (including Sézary Syndrome).	red blood cells 0.477836 cancer treatment 0.542958 body 0.529399 type 0.500535 mycosis fungoides 0.975868 electron beam radiation 0.477517 PDQ cancer information 0.525493 clinical trial search 0.486291 white blood cells 0.528751 abnormal blood cells 0.470219 clinical trials 0.793086 Natural killer cells 0.470828 cancer information summary 0.501852 clinical trial 0.600812 mycosis fungoides cells 0.530781 patients 0.476603 blood cells 0.579852 skin electron beam 0.532192 malignant tumor cells 0.48923 NCI PDQ cancer 0.469777 Treatment Option Overview 0.471891 total skin electron 0.534719 radiation therapy 0.663697 Treatment Editorial Board 0.471648 beam radiation therapy 0.484689	treatment 0.659413 myeloid stem cell 0.465408 immature blood cells 0.46931 photodynamic therapy 0.471883 Recurrent mycosis fungoides 0.52314 mycosis fungoides spreads 0.498418 skin 0.583221 cancer cells 0.698589 lymphoid stem cell 0.465897 treatment clinical trials 0.487816 blood stem cells 0.499083 National Cancer Institute 0.538216 sézary syndrome 0.849117 normal cells 0.5004 new treatment 0.509312 Skin Cancer Treatment 0.502202 External radiation therapy 0.473547 metastatic mycosis fungoides 0.5 non-hodgkin lymphoma 0.536949 bone marrow 0.486285 cancer clinical trials 0.50691 stage 0.517644 cancer 0.856203 information 0.542975	CLICK HERE
1597	National Cancer Institute	Html	en	Renal Cell Cancer Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of renal cell cancer.	clinical trial 0.367191 treatment 0.366101 new treatment 0.252341 cancer treatment 0.244932 renal cell cancer 0.966092 blood vessels 0.211783 cancer cells 0.348136 body 0.231872 blood 0.231431 PDQ cancer information 0.239381	kidney 0.278858 clinical trial search 0.226212 cancer clinical trials 0.248142 palliative therapy 0.250231 radiation therapy 0.306887 National Cancer Institute 0.215087 clinical trials 0.539491 information 0.242909 Recurrent renal cell 0.204258 nearby lymph nodes 0.232113	CLICK HERE
1681	National Cancer Institute	Html	en	Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of pheochromocytoma and paraganglioma.	predictive genetic testing 0.546307 SDHD gene mutations 0.515875 Eur J Endocrinol 0.518575 Mayo Clin Proc 0.6693 Cancer Registry Data 0.51437 Engl J Med 0.526531 gastric stromal sarcoma 0.611907 hypertensive patients 0.517324 Carney JA 0.521579 relatively low specificity 0.519758 succinate dehydrogenase subunit 0.517616 family members 0.522519 secondary hypertension 0.527498 extra-adrenal paraganglioma 0.541601 patients 0.689236 pheochromocytoma 0.980646 recurrent disease 0.531233 Nat Genet 0.533038 Anderson GH Jr 0.515558 Clin Endocrinol Metab 0.833928 Young WF Jr 0.733968 blood pressure clinic 0.513794 certified genetic counselor 0.538726 apparently sporadic pheochromocytomas 0.521625 familial pheochromocytoma 0.636594	specific genetic mutation 0.541317 et al. 0.643614 Acta Med Scand 0.520675 sporadic pheochromocytoma 0.676644 hereditary syndromes 0.539521 Hum Mol Genet 0.527412 Additional functional imaging 0.525724 lower baseline risk 0.519277 nonsyndromic pheochromocytoma 0.636272 Endocrinol Metab Clin 0.581599 asymptomatic at-risk family 0.525477 hereditary syndrome 0.626484 CT imaging 0.547645 functional imaging alternatives 0.520963 Abstract 0.735482 unilateral pheochromocytoma 0.711773 Arch Intern Med 0.518188 carney triad 0.518951 high false-positive rate 0.514503 succinate dehydrogenase 0.527913 genetic testing 0.726041 apparently sporadic cases 0.53892 familial paraganglioma 0.533705 Cancer Genetics Services 0.525523	CLICK HERE
1683	National Cancer Institute	Html	en	Levels of Evidence for Cancer Genetics Studies (PDQ®)–Health Professional Version	Information about how to weigh the strength of the evidence obtained in cancer genetics research studies.	evidence 0.90522 founder pathogenic variants 0.607927 particular familial cancer 0.575132 uncertain clinical validity 0.627303 Additional molecular studies 0.560778 naturally occurring populations 0.544454 cancer genetics 0.691619 specific cancer predisposition 0.575811 genetic variant 0.654078 stringent clinical criteria 0.562657 public health decisions 0.545838 linkage studies 0.6723 PDQ editorial boards 0.553508 genetic trait 0.600811 pathogenic variant 0.819319 genetic assessment 0.654469 specific genetic variant 0.631207 study design 0.568851 similar family histories 0.661472 randomized clinical trials 0.593831 genetic tests 0.632916 clinical condition 0.678588 specific pathogenic variant 0.648511 different cut-off points 0.557549 early breast cancer 0.569442	variant classification 0.551223 new evidence 0.642949 particular genetic mode 0.574967 family history information 0.559208 dramatic cancer aggregation 0.566187 general population 0.606787 strongest evidence 0.703859 analytic validity 0.833034 specific cancer susceptibility 0.578074 positive test result 0.563425 term pathogenic variant 0.684458 pathogenic variants 0.624356 positive test 0.563624 different expert panels 0.553682 cancer genetic testing 0.643637 well-designed quasi-experimental studies 0.586898 limited evidence 0.559825 risk management decisions 0.57484 well-designed descriptive studies 0.584976 cancer genetics testing 0.58578 clinical validity 0.930443 cancer risk 0.638478 cancer 0.767744 Cancer Genetics Overview 0.616265	CLICK HERE
1810	National Cancer Institute	Html	es	Tratamiento del cáncer de páncreas (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de páncreas.	resectable pancreatic 0.421757 Sin embargo 0.468358 largo plazo 0.439685 chemotherapy following curative 0.48776 Tumor Study Group 0.478506 curative resection 0.550476 fase iii 0.665649 Natl Cancer Inst 0.419755 after curative resection 0.455925 Arch Surg 0.451242 effective adjuvant combined 0.42796 gemcitabina versus 0.464125 quimiorradioterapia posoperatoria 0.420132 Gastrointestinal Intergroup 0.4265 Cameron JL 0.507923 periampullary region 0.42716 patients with 0.44756 randomized controlled 0.421891 Conlon KC 0.442167 Lillemoe KD 0.42689 EORTC gastrointestinal tract 0.428698 meses vs 0.421884 gastrointestinal tract 0.431387 following curative resection 0.474649 Yeo CJ 0.5451	M0 T2 0.428111 M0 T1 0.424975 chemotherapy after resection 0.463442 Regine WF 0.420404 M0 T3 0.428453 pancreatic cancer 0.97706 as risk factors 0.421112 postoperative adjuvant chemoradiation 0.455288 versus gemcitabina 0.456328 Surg Oncol 0.435512 patients with resected 0.42485 Gastrointestinal Tumor Study 0.48648 páncreas estadio 0.439198 régimen off 0.443587 Grochow LB 0.426604 estadio iii 0.623435 Abrams RA 0.46019 Gy XRT 0.450407 Adjuvant chemotherapy with 0.456373 Stocken DD 0.455773 Oncology Group 0.420611 adjuvant combined 0.442249 quimioterapia posoperatoria 0.432032 5-fluorouracil after curative 0.42675	CLICK HERE
1853	National Cancer Institute	Html	es	Tratamiento de los tumores de hipófisis (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de los tumores de hipófisis.	pituitary tumors 0.728644 apoplejía hipofisaria 0.422211 general adenomas gonadotropos 0.447102 gonadotroph adenomas 0.512689 Sin embargo 0.480821 pituitary carcinoma 0.526345 adenomas lactótropos 0.483762 Endocrinol Invest 0.422936 tumores gonadotropos 0.422871 tumores celulares productores 0.42814 tumores productores 0.449036 Couldwell WT 0.451028 Asa SL 0.451558 tumores endocrinos 0.42423 adenomas corticotropos 0.483433 Di Sarno A 0.42917 Kovacs KT 0.42311 Clin Endocrinol Metab 0.711638 ACTH secreting pituitary 0.441137 Neurosurg Focus 0.422719 adenomas gonadotropos 0.63232 Yeh PJ 0.462771 Chen JW 0.457982 case report 0.519998 Ezzat S 0.451653	Levy A 0.45572 adenomas tirotropos 0.47717 Long-term survival with 0.423122 pituitary adenoma 0.992345 Scheithauer BW 0.524034 invasive pituitary tumors 0.460006 adenomas somatotropos 0.480811 Subclinical adenomas 0.440961 Surg Oncol 0.463881 to functional classification 0.441148 occult adenomas 0.439818 secreting pituitary neoplasia 0.430766 Neurol Neurosurg Psychiatry 0.513976 Colao A 0.424448 Kovacs K 0.448425 with acth-secreting carcinoma 0.427044 systematic review 0.423136 Laws ER Jr 0.437305 pituitary tumors with 0.465003 medical management 0.455666 thyrotropin-secreting pituitary adenoma 0.457958 Adenomas benignos 0.45094 hipófisis productores 0.733158 Horvath E 0.435361	CLICK HERE
2035	National Cancer Institute	Html	es	Prevención del cáncer de próstata (PDQ®)–Versión para pacientes	Sumario de información revisada por expertos sobre los factores que pueden influir en el riesgo de cáncer de próstata y sobre la investigación dirigida a la prevención de esta enfermedad.	Cancer Events Trial 0.485531 principal hormona 0.450019 hiperplasia prostática benigna 0.693996 siguientes aspectos 0.54196 voluntarios sanos 0.443459 sistema urinario masculino 0.492083 protección baje 0.460121 sexuales masculinas 0.54225 características sexuales masculinas 0.494615 productos lácteos 0.532437 National Cancer Institute 0.461613 causa problemas 0.446148 siguientes riesgos 0.444876 alto contenido 0.439101 vitamina e 0.679303 Instituto Nacional 0.499716 hormonas masculinas 0.456898	hormonas sexuales masculinas 0.490983 Cancer Prevention Trial 0.881744 próstata.ampliar próstata 0.748136 ensayo pcpt 0.447994 siguientes factores 0.946442 Physician Data Query 0.60903 Estados Unidos 0.553599 suficiente ejercicio 0.453444 prevención revisa 0.462505 Antecedentes familiares 0.554865 PDQ Prevención 0.512729 aparato reproductor masculino 0.494928 Prostate Cancer Prevention 0.495264 suficiente folato 0.56107 Prostate Cancer 0.530877 siguientes sumarios 0.505076	CLICK HERE
16649	National Cancer Institute	Html	en	Track 4: Cancer Prevention Product Research and Review for Postdoctoral Research Fellows	NCI and FDA collaborate to train individuals in the medical product development and application process. Learn more about this cancer training program.	regulatory research 0.47135 pharmacology/toxicology branch 0.439495 cancer prevention trials 0.576995 limited preclinical data 0.531474 NCI fellows 0.61137 non-clinical fellows 0.591774 FDA scientific review 0.564313 related regulatory experience 0.528845 Fellowship Program 0.512424 IRB approval process 0.551558 treatment endpoints 0.45623 application guidelines 0.486651 clinical trials 0.471521 translational research 0.452228 research goals 0.442846 early detection 0.562481 early detection trials 0.555324 various regulatory activities 0.534652 acceptable drug toxicity 0.528586 Regulatory Review Fellowships 0.520225 approval processes 0.437768 multidisciplinary cancer prevention 0.570632 particular product division 0.535827 FDA Centers 0.561203	research mentors 0.452404 product standards 0.439879 Cancer Prevention Fellowship 0.546138 regulatory pathways 0.442598 professional development activities 0.534321 earliest start date 0.490036 cancer prevention 0.942415 critical ethical issues 0.519948 product research 0.479994 clinical investigation 0.441391 appropriate clinical endpoints 0.603566 Effective Presentations Workshop 0.512774 human research subjects 0.569744 guidance document development 0.508388 public health 0.546598 Fellowship Program staff 0.506185 NCI-FDA Research 0.441603 Molecular Prevention Laboratory 0.53668 cancer prevention research 0.787983 research interests 0.453508 device development 0.439712 chemoprevention trials 0.587824 research-related regulatory overview 0.574022 Fellows Research Meetings 0.732161	CLICK HERE